Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum

M. Hosokawa, H. Tsukada, K. Fukuda, M. Oya, M. Onomura, H. Nakamura, M. Kodama, Y. Yamada and Y. Seino
Journal of Pharmacology and Experimental Therapeutics September 1999, 290 (3) 1080-1084;
M. Hosokawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Tsukada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Fukuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Oya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Onomura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Nakamura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Kodama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Yamada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Seino
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Troglitazone is a new, orally effective antidiabetic agent that decreases plasma glucose in obese patients with non-insulin-dependent diabetes mellitus. Unfortunately, troglitazone also has a propensity to cause edema. This study was designed to determine how troglitazone affects intestinal ion transport and water absorption. Short circuit current (Isc) was measured in rat and human duodenal mucosa in Ussing chambers. Five minutes later, the serosal addition of troglitazone caused Isc to decrease gradually, and after 50 min, Isc reached the peak of decrease. EC50values and maximum response to Isc in rat and human mucosa were 8.4 and 8.7 μM and 8.56 ± 1.0 and 8.00 ± 2.0 μA/cm2, respectively. In an HCO3−/CO2-free system, the decrease in Isc caused by troglitazone was 1.31 ± 0.83 μA/cm2. When 10 mM acetazolamide was preadministered, the small decrease in Isc evoked by troglitazone (20 μM) was 4.56 ± 0.22 μA/cm2, whereas the preadministration of 100 μM amiloride and 100 nM tetrodotoxin did not influence the decrease in Isc evoked by troglitazone. The serosal preadministration of 100 nM vasoactive intestinal peptide potently enhanced the decrease in Iscevoked by 20 μM troglitazone (21.1 ± 1.63 μA/cm2). The cyclic AMP contents of rat duodenal mucosa incubated with and without troglitazone (20 μM) for 50 min were 3.2 ± 0.25 and 5.8 ± 0.46 pmol/mg protein, respectively (P < .01). These results indicate that the ionic basis for the decrease in Isc that is induced by troglitazone may be inhibition of electrogenic bicarbonate secretion. The alteration of intestinal ion transport by troglitazone could cause edema.

Footnotes

  • Send reprint requests to: Dr. Masaya Hosokawa, Department of Metabolism and Clinical Nutrition, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8507, Japan. E-mail:hosokawa{at}metab.kuhp.kyoto-u.ac.jp

  • ↵1 This study was supported by a grant-in-aid for Creative Basic Research (10670468 and 10NP0210) from the Ministry of Education, Science, Sports and Culture, Japan and a grant for the “Research for the Future” Program from the Japan Society for the Promotion of Science (JSPS-RFTF97I00201).

  • Abbreviations:
    Isc
    short circuit current
    TTX
    tetrodotoxin
    cAMP
    cyclic AMP
    DMSO
    dimethyl sulfoxide
    VIP
    vasoactive intestinal peptide
    • Received February 8, 1998.
    • Accepted April 29, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 290 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 290, Issue 3
1 Sep 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum

M. Hosokawa, H. Tsukada, K. Fukuda, M. Oya, M. Onomura, H. Nakamura, M. Kodama, Y. Yamada and Y. Seino
Journal of Pharmacology and Experimental Therapeutics September 1, 1999, 290 (3) 1080-1084;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum

M. Hosokawa, H. Tsukada, K. Fukuda, M. Oya, M. Onomura, H. Nakamura, M. Kodama, Y. Yamada and Y. Seino
Journal of Pharmacology and Experimental Therapeutics September 1, 1999, 290 (3) 1080-1084;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Meeting Report for the ASPET–Ray Fuller Symposium: Cellular Mechanisms and Novel Strategies for Pain Control
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics